Advancing Rare Disease Clinical Trials With Point-Of-Need Eye Assessments

During the COVID-19 pandemic, Applied Genetic Technologies Corporation (AGTC) faced significant hurdles in enrolling participants for the SKYLINE trial for X-linked Retinitis Pigmentosa (XLRP) and Achromatopsia (ACHM) due to travel restrictions and site limitations. To overcome these challenges, AGTC collaborated with 20/20 Onsite to deploy Mobile Vision Clinics (MVCs).

These clinics, equipped with advanced ophthalmic tools, enabled assessments and pre-screenings to be conducted at patients' homes. This innovative approach facilitated the completion of 150 assessments across 24 states, allowing AGTC to maintain trial momentum and surpass enrollment goals with 14 participants. The convenience and safety of the MVCs were highly rated by 97% of participants, helping AGTC avoid costly delays and successfully meet their clinical trial objectives. The MVCs proved essential in AGTC's success and present a viable model for addressing similar challenges in clinical research during the pandemic.